Home › Companies › KINIKSA PHARMACEUTICALS LTD. › 2023-2024

KINIKSA PHARMACEUTICALS LTD. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and KINIKSA PHARMACEUTICALS LTD.’s Form 8-K, filed 2024-06-05 (Item 5.07 on EDGAR). Page generated 02 October 2026.

8Reported items
186Asset managers
1,619Fund votes
2024-06-05Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore KINIKSA PHARMACEUTICALS LTD. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by KINIKSA PHARMACEUTICALS LTD.

These tallies are KINIKSA PHARMACEUTICALS LTD.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-05 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

KINIKSA PHARMACEUTICALS LTD. — official shareholder meeting results, meeting held 2024-06-05
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Felix J. Baker, Ph.D.	31,885,339	--	--	15,812,807	3,067,059	Majority: yes
Elect Director: Tracey L. McCain	46,746,052	--	--	952,094	3,067,059	Majority: yes
Elect Director: Kimberly J. Popovits	46,745,428	--	--	952,718	3,067,059	Majority: yes
Proposal 2: The (a) appointment of PricewaterhouseCoopers LLP as the Company's auditor until the close of the Company's next Annual Meeting of Shareholders, (b) delegation to the Company's Board of Directors, through the Audit Committee of the Board of Directo	50,512,245	217,508	35,452	--	0	Majority: yes
Proposal 3: The approval, on a non - binding, advisory basis, of the compensation of our named executive officers as disclosed in the Company's proxy statement for the Annual Meeting pursuant to the applicable compensation disclosure rules of the Securities an	46,903,551	469,616	324,979	--	3,067,059	Majority: yes
Proposal 1: The election of Felix J	61,460,949	501,355	274,060	274,060	--	Majority: yes

Source: KINIKSA PHARMACEUTICALS LTD., Form 8-K, filed with the SEC on 2024-06-05 — read the filing on EDGAR.

How asset managers voted at the KINIKSA PHARMACEUTICALS LTD. 2023-2024 meeting

Each item below shows how the 186 asset managers that disclosed a KINIKSA PHARMACEUTICALS LTD. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of KINIKSA PHARMACEUTICALS LTD.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding advisory basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2024 Annual Meeting pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 11 wordings of this item as funds reported it.

99.0% Majority: yes · of votes cast

FOR 99.0%

FOR: 46,903,551AGAINST: 469,616

KINIKSA PHARMACEUTICALS LTD.’s own tally for this item (“Proposal 3: The approval, on a non - binding, advisory basis, of the compensation of our named executive officers as disclosed in the Company's proxy statement for the Annual Meeting pursuant to the applicable compensati”): 46,903,551 for, 469,616 against, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 185 asset managers below cast 99.2% of the shares they voted on this item FOR (33,137,558 for, 255,464 against).

FOR 99.1%

FOR: 33,137,558 (99.2%)AGAINST: 255,464 (0.8%)ABSTAIN: 17,844 (0.1%)NOT VOTED: 26 (0.0%)UNKNOWN: 7 (0.0%)

Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the named executive officers as disclosed in ” at KINIKSA PHARMACEUTICALS LTD., 2023-2024
Asset manager	For	Against	Vote
BlackRock	3,602,409	8,649	For
Fairmount Funds Management LLC	3,204,841	0	For
HHLR ADVISORS, LTD.	3,135,735	0	For
Vanguard	2,986,210	0	For
BAKER BROS. ADVISORS LP	2,799,577	0	For
State Street	2,365,992	327	For
PICTET ASSET MANAGEMENT SA	1,344,336	0	For
Rubric Capital Management LP	1,159,536	0	For
BRAIDWELL LP	1,034,733	0	For
Nuveen	835,359	0	For
TIAA	834,180	0	For
SEI	595,369	0	For
ArrowMark Colorado Holdings LLC	555,469	0	For
Fidelity	486,141	0	For
Granahan Investment Management, LLC	482,190	0	For
GEODE CAPITAL MANAGEMENT, LLC	462,198	0	For
RICE HALL JAMES & ASSOCIATES, LLC	448,394	0	For
Dimensional	441,818	0	For
DRIEHAUS CAPITAL MANAGEMENT LLC	403,318	0	For
Altitude Crest Partners Inc.	400,441	0	For
Goldman Sachs	299,446	0	For
Prudential/PGIM	263,248	3,950	For
Connor, Clark & Lunn Investment Management Ltd.	249,542	0	For
Allspring	243,161	0	For
DE Shaw	195,950	0	For

Showing the 25 largest of 185 asset managers. See all 185 in the interactive database.

2. Election of Class III Directors to serve until the 2027 Annual Meeting of Shareholders, and until their respective successors have been duly elected and qualified: Felix J Baker, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

67% Majority: yes · of votes cast

FOR 67%WITHHELD 33%

FOR: 31,885,339WITHHELD: 15,812,807

KINIKSA PHARMACEUTICALS LTD.’s own tally for this item (“Elect Director: Felix J. Baker, Ph.D.”): 31,885,339 for, 15,812,807 withheld, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 70 asset managers below cast 100% of the shares they voted on this item FOR (3,156,023 for, 0 against).

FOR 32%ABSTAIN 68%

FOR: 3,156,023 (32.0%)ABSTAIN: 6,701,599 (68.0%)

Largest asset managers voting on “Election of Class III Directors to serve until the 2027 Annual Meeting of Shareholders, and until their respec” at KINIKSA PHARMACEUTICALS LTD., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	2,937,249	0	For
BlackRock	0	1,901,966	Abstain
State Street	0	868,032	Abstain
TIAA	0	834,180	Abstain
Fidelity	0	484,539	Abstain
Dimensional	0	380,376	Abstain
SEI	0	296,344	Abstain
Goldman Sachs	0	238,411	Abstain
MERIDIAN FUND INC	0	191,844	Abstain
Jackson National	0	144,668	Abstain
Allspring	0	121,237	Abstain
Victory Capital	0	103,127	Abstain
Equitable	0	93,219	Abstain
Charles Schwab	0	84,155	Abstain
DWS	0	83,435	Abstain
DRIEHAUS MUTUAL FUNDS	0	80,854	Abstain
MFS	0	78,153	Abstain
Advisors' Inner Circle Fund III	74,490	0	For
QUANTITATIVE MASTER SERIES LLC	0	59,247	Abstain
Prudential/PGIM	57,600	0	For
CLEARWATER INVESTMENT TRUST	0	47,116	Abstain
Direxion Shares ETF Trust	0	46,669	Abstain
Lincoln Financial	0	45,636	Abstain
RBB FUND, INC.	0	44,566	Abstain
Nationwide	286	41,801	Abstain

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

3. Election of Class III Directors to serve until the 2027 Annual Meeting of Shareholders, and until their respective successors have been duly elected and qualified: Kimberly J. Popovits

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 46,745,428WITHHELD: 952,718

KINIKSA PHARMACEUTICALS LTD.’s own tally for this item (“Elect Director: Kimberly J. Popovits”): 46,745,428 for, 952,718 withheld, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 70 asset managers below cast 100% of the shares they voted on this item FOR (9,408,878 for, 0 against).

FOR 95%

FOR: 9,408,878 (95.4%)ABSTAIN: 448,744 (4.6%)

Largest asset managers voting on “Election of Class III Directors to serve until the 2027 Annual Meeting of Shareholders, and until their respec” at KINIKSA PHARMACEUTICALS LTD., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	2,937,249	0	For
BlackRock	1,901,966	0	For
State Street	868,032	0	For
TIAA	834,180	0	For
Fidelity	484,539	0	For
Dimensional	0	380,376	Abstain
SEI	296,344	0	For
Goldman Sachs	238,411	0	For
MERIDIAN FUND INC	191,844	0	For
Jackson National	137,928	6,740	For
Allspring	121,237	0	For
Victory Capital	103,127	0	For
Equitable	53,659	39,560	For
Charles Schwab	84,155	0	For
DWS	83,435	0	For
DRIEHAUS MUTUAL FUNDS	80,854	0	For
MFS	78,153	0	For
Advisors' Inner Circle Fund III	74,490	0	For
QUANTITATIVE MASTER SERIES LLC	59,247	0	For
Prudential/PGIM	57,600	0	For
CLEARWATER INVESTMENT TRUST	47,116	0	For
Direxion Shares ETF Trust	46,669	0	For
Lincoln Financial	41,412	4,224	For
RBB FUND, INC.	44,566	0	For
Nationwide	42,087	0	For

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

4. Election of Class III Directors to serve until the 2027 Annual Meeting of Shareholders, and until their respective successors have been duly elected and qualified: Tracey L. McCain

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 46,746,052WITHHELD: 952,094

KINIKSA PHARMACEUTICALS LTD.’s own tally for this item (“Elect Director: Tracey L. McCain”): 46,746,052 for, 952,094 withheld, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 70 asset managers below cast 100% of the shares they voted on this item FOR (9,408,878 for, 0 against).

FOR 95%

FOR: 9,408,878 (95.4%)ABSTAIN: 448,744 (4.6%)

Largest asset managers voting on “Election of Class III Directors to serve until the 2027 Annual Meeting of Shareholders, and until their respec” at KINIKSA PHARMACEUTICALS LTD., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	2,937,249	0	For
BlackRock	1,901,966	0	For
State Street	868,032	0	For
TIAA	834,180	0	For
Fidelity	484,539	0	For
Dimensional	0	380,376	Abstain
SEI	296,344	0	For
Goldman Sachs	238,411	0	For
MERIDIAN FUND INC	191,844	0	For
Jackson National	137,928	6,740	For
Allspring	121,237	0	For
Victory Capital	103,127	0	For
Equitable	53,659	39,560	For
Charles Schwab	84,155	0	For
DWS	83,435	0	For
DRIEHAUS MUTUAL FUNDS	80,854	0	For
MFS	78,153	0	For
Advisors' Inner Circle Fund III	74,490	0	For
QUANTITATIVE MASTER SERIES LLC	59,247	0	For
Prudential/PGIM	57,600	0	For
CLEARWATER INVESTMENT TRUST	47,116	0	For
Direxion Shares ETF Trust	46,669	0	For
Lincoln Financial	41,412	4,224	For
RBB FUND, INC.	44,566	0	For
Nationwide	42,087	0	For

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

5. To approve the Scheme of Arrangement attached to the accompanying proxy statement as Annex A among the Company and its shareholders.

EXTRAORDINARY TRANSACTIONSCORPORATE GOVERNANCE

Combines 2 wordings of this item as funds reported it.

99.6% fund support · no official result

FOR 99.4%

The 69 asset managers below cast 99.6% of the shares they voted on this item FOR (9,800,514 for, 39,223 against).

FOR: 9,800,514 (99.4%)AGAINST: 39,223 (0.4%)ABSTAIN: 17,844 (0.2%)

Largest asset managers voting on “To approve the Scheme of Arrangement attached to the accompanying proxy statement as Annex A among the Company” at KINIKSA PHARMACEUTICALS LTD., 2023-2024
Asset manager	For	Against	Vote
Vanguard	2,937,249	0	For
BlackRock	1,901,966	0	For
State Street	868,032	0	For
TIAA	834,180	0	For
Fidelity	484,539	0	For
Dimensional	380,376	0	For
SEI	296,344	0	For
Goldman Sachs	238,411	0	For
MERIDIAN FUND INC	191,844	0	For
Jackson National	144,668	0	For
Allspring	121,237	0	For
Victory Capital	103,127	0	For
Equitable	93,219	0	For
Charles Schwab	84,155	0	For
DWS	83,435	0	For
DRIEHAUS MUTUAL FUNDS	80,854	0	For
MFS	78,153	0	For
Advisors' Inner Circle Fund III	74,490	0	For
QUANTITATIVE MASTER SERIES LLC	59,247	0	For
Prudential/PGIM	57,600	0	For
CLEARWATER INVESTMENT TRUST	7,893	39,223	Against
Direxion Shares ETF Trust	46,669	0	For
Lincoln Financial	45,636	0	For
RBB FUND, INC.	44,566	0	For
Nationwide	42,087	0	For

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

6. The appointment of PricewaterhouseCoopers LLP as the Company's auditor until the close of the Company's next Annual Meeting of Shareholders, the delegation to the Company's Board of Directors, through its Audit Committee, of the authority to set the auditor's remuneration for such period, and the ratification of the appointment of PricewaterhouseCoopers LLP, as the Company's independent registered

AUDIT-RELATEDMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%

FOR: 50,512,245AGAINST: 217,508

KINIKSA PHARMACEUTICALS LTD.’s own tally for this item (“Proposal 2: The (a) appointment of PricewaterhouseCoopers LLP as the Company's auditor until the close of the Company's next Annual Meeting of Shareholders, (b) delegation to the Company's Board of Directors, through the”): 50,512,245 for, 217,508 against, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 69 asset managers below cast 99.2% of the shares they voted on this item FOR (9,765,247 for, 74,490 against).

FOR 99.0%

FOR: 9,765,247 (99.1%)AGAINST: 74,490 (0.8%)ABSTAIN: 17,844 (0.2%)

Largest asset managers voting on “The appointment of PricewaterhouseCoopers LLP as the Company's auditor until the close of the Company's next A” at KINIKSA PHARMACEUTICALS LTD., 2023-2024
Asset manager	For	Against	Vote
Vanguard	2,937,249	0	For
BlackRock	1,901,966	0	For
State Street	868,032	0	For
TIAA	834,180	0	For
Fidelity	484,539	0	For
Dimensional	380,376	0	For
SEI	296,344	0	For
Goldman Sachs	238,411	0	For
MERIDIAN FUND INC	191,844	0	For
Jackson National	144,668	0	For
Allspring	121,237	0	For
Victory Capital	103,127	0	For
Equitable	93,219	0	For
Charles Schwab	84,155	0	For
DWS	83,435	0	For
DRIEHAUS MUTUAL FUNDS	80,854	0	For
MFS	78,153	0	For
Advisors' Inner Circle Fund III	0	74,490	Against
QUANTITATIVE MASTER SERIES LLC	59,247	0	For
Prudential/PGIM	57,600	0	For
CLEARWATER INVESTMENT TRUST	47,116	0	For
Direxion Shares ETF Trust	46,669	0	For
Lincoln Financial	45,636	0	For
RBB FUND, INC.	44,566	0	For
Nationwide	42,087	0	For

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

7. To approve a motion to adjourn the Special Court-Ordered Meeting of the shareholders of the Company (the "Redomiciliation Meeting") to a later date to solicit additional proxies if there are insufficient proxies to approve the Scheme of Arrangement at the time of the Redomiciliation Meeting.

CORPORATE GOVERNANCE

Combines 2 wordings of this item as funds reported it.

87% fund support · no official result

FOR 86%13%

The 67 asset managers below cast 87% of the shares they voted on this item FOR (8,440,698 for, 1,316,292 against).

FOR: 8,440,698 (86.4%)AGAINST: 1,316,292 (13.5%)ABSTAIN: 17,844 (0.2%)

Largest asset managers voting on “To approve a motion to adjourn the Special Court-Ordered Meeting of the shareholders of the Company (the "Redo” at KINIKSA PHARMACEUTICALS LTD., 2023-2024
Asset manager	For	Against	Vote
Vanguard	2,937,249	0	For
BlackRock	1,901,966	0	For
State Street	0	868,032	Against
TIAA	834,180	0	For
Fidelity	67,139	417,400	Against
Dimensional	380,376	0	For
SEI	296,344	0	For
Goldman Sachs	238,411	0	For
MERIDIAN FUND INC	191,844	0	For
Jackson National	144,668	0	For
Allspring	121,237	0	For
Victory Capital	103,127	0	For
Equitable	93,219	0	For
Charles Schwab	84,155	0	For
DWS	83,435	0	For
DRIEHAUS MUTUAL FUNDS	80,854	0	For
MFS	78,153	0	For
QUANTITATIVE MASTER SERIES LLC	59,247	0	For
Prudential/PGIM	57,600	0	For
CLEARWATER INVESTMENT TRUST	47,116	0	For
Direxion Shares ETF Trust	46,669	0	For
Lincoln Financial	18,936	26,700	Against
RBB FUND, INC.	44,566	0	For
Nationwide	42,087	0	For
1290 Funds	35,868	0	For

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

8. TO APPROVE A MOTION TO ADJOURN THE SPECIAL COURT-ORDERED MEETING OF THE SHAREHOLDERS OF THE COMPANY (THE REDOMICILIATION MEETING&QUOT) TO A LATER DATE TO SOLICIT ADDITIONAL PROXIES IF THERE ARE INSUFFICIENT PROXIES TO APPROVE THE SCHEME OF ARRANGEMENT AT THE TIME OF THE REDOMICILIATION MEETING. &QUOT

CORPORATE GOVERNANCE

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (82,747 for, 0 against).

FOR: 82,747 (100.0%)

Largest asset managers voting on “TO APPROVE A MOTION TO ADJOURN THE SPECIAL COURT-ORDERED MEETING OF THE SHAREHOLDERS OF THE COMPANY (THE REDOM” at KINIKSA PHARMACEUTICALS LTD., 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
Advisors' Inner Circle Fund III	74,490	0	0	0	For
TIMOTHY PLAN	8,257	0	0	0	For

Largest KINIKSA PHARMACEUTICALS LTD. shareholders voting in 2023-2024

Ranked by the number of KINIKSA PHARMACEUTICALS LTD. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting.

Top KINIKSA PHARMACEUTICALS LTD. shareholders by shares voted, 2023-2024
#	Asset manager	Shares voted
1	BlackRock	3,611,058
2	Fairmount Funds Management LLC	3,204,841
3	HHLR ADVISORS, LTD.	3,135,735
4	Vanguard	2,986,210
5	BAKER BROS. ADVISORS LP	2,799,577
6	State Street	2,366,319
7	PICTET ASSET MANAGEMENT SA	1,344,336
8	Rubric Capital Management LP	1,159,536
9	BRAIDWELL LP	1,034,733
10	Nuveen	835,359

Shown as share counts, not percentages: no shares-outstanding figure has been matched to KINIKSA PHARMACEUTICALS LTD. for the 2023-2024 season, so there is no denominator to divide by.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At KINIKSA PHARMACEUTICALS LTD.'s shareholder meeting held 2024-06-05, in the 2023-2024 proxy season, 186 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,619 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of the named executive officers… — FOR was 99.0% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: KINIKSA PHARMACEUTICALS LTD.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-05.

KINIKSA PHARMACEUTICALS LTD. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.